Metastin Derivative Sustained-Release via Lactic Acid Polymer Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sustained-release formulations for metastin derivatives require high dosages and frequent administration, leading to side effects and inconvenience, and lack long-term stability in medicinal effects.
Innovation Solution
A sustained-release formulation containing a metastin derivative or its salt combined with a lactic acid polymer of weight average molecular weight between 5,000 to 40,000, specifically designed for slow and stable release over several weeks or months, using emulsification methods like W/O/W or O/W emulsions followed by in-water drying to create microcapsules or rod-form moldings.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If a sustained-release formulation is developed to reduce administration frequency and improve patient convenience, then the duration of action is extended, but the formulation complexity increases
Solution Approach 1:
The patent employs composite materials by combining metastin derivative with lactic acid polymer (a biodegradable polymer) to create a sustained-release formulation. The polymer matrix provides controlled release while being biocompatible and biodegradable, resolving the contradiction between extended duration and formulation complexity through material science rather than complex device design
Solution Approach 2:
The patent utilizes parameter changes by controlling the molecular weight of the lactic acid polymer (5,000 to 40,000) and adjusting the formulation composition to achieve desired release profiles. By optimizing these parameters, the formulation achieves prolonged action without requiring complex multi-component systems
2Quantity of substance
If high dosage amount is administered to achieve medicinal effects, then the therapeutic effect is improved, but side effects increase
Solution Approach 1:
The sustained-release formulation enables periodic action by maintaining therapeutic drug levels over an extended period (weeks to months). This allows for less frequent administration while maintaining effective dosage, thereby reducing the peak-dose related side effects while preserving therapeutic efficacy
Solution Approach 2:
The formulation achieves continuity of useful action through controlled release of metastin derivative from the polymer matrix. This maintains steady therapeutic levels in the body, avoiding the fluctuations between high peak doses (causing side effects) and low trough doses (reducing efficacy)
3Reliability
If frequent administration is required to maintain therapeutic effect, then the medicinal effect is maintained, but patient convenience deteriorates
Solution Approach 1:
The formulation applies dynamics by designing a time-dependent release system where the drug is released at a controlled rate over time. The lactic acid polymer degrades progressively, providing continuous drug release that maintains therapeutic effect while reducing administration frequency, thus improving patient convenience without sacrificing reliability
4Productivity
If a sustained-release formulation is designed for long-term release, then the frequency of administration is reduced, but the stability requirements increase
Solution Approach 1:
The lactic acid polymer acts as an intermediary between the metastin derivative and the biological environment. It provides a stable matrix that protects the active ingredient while enabling controlled release over time, thus achieving long-term productivity improvement without compromising formulation stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves prolonged medicinal effects with reduced frequency of administration, improved patient convenience, and enhanced stability and safety, providing effective treatment for various cancers and other conditions with minimal toxicity.
Implementation Method 1
a sustained-release formulation which contains a metastin derivative or a salt thereof and a lactic acid polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof... slowly releases a metastin derivative over a long period of time
Implementation Method 2
lactic acid polymer having a weight average molecular weight of about 5,000 to about 40,000... slowly releases a metastin derivative over a long period of time
Implementation Method 3
using emulsification methods like W/O/W or O/W emulsions followed by in-water drying to create microcapsules or rod-form moldings
Data Source
AI summary
The present invention relates to a sustained-release formulation comprising a metastin derivative and a lactic polymer having a weight average molecular weight of about 5,000 to about 40,000 or a salt thereof. The sustained-release formulation of the present invention slowly and stably releases compound (I) or a salt thereof over a long period of time and exerts medicinal effects of compound (I) or a salt thereof over a long period of time. Furthermore, the sustained-release formulation of the present invention, which improves patient's convenience by reducing frequency of administration, is an excellent formulation as a clinical medicine.